Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $51.04 and last traded at $50.92, with a volume of 159797 shares trading hands. The stock had previously closed at $50.77.
Gemini Therapeutics Stock Performance
The company has a market capitalization of $2.04 billion, a PE ratio of -46.99 and a beta of -0.12. The stock has a fifty day moving average of $48.93 and a 200 day moving average of $41.74.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What is an Earnings Surprise?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
